AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01988077 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ipilimumab 5 MG/ML Injection [Yervoy]
Description: 2 treatments of Ipilimumab before transfer of TIL and 2 treatments of Ipilimumab after TIL
Study NCT03057184 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention will consist of 8 weekly sessions, with a duration of 90 minutes. Although each intervention is adapted to the specific behavioral problems
Study NCT01822925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-9801 300mg
Description: 300 mg of DA-9801 in tablet form, 100 mg to be taken 3 times daily for 12 weeks.
Study NCT01822925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-9801 600mg
Description: 600 mg of DA-9801 in tablet form, 200 mg to be taken 3 times daily for 12 weeks.
Study NCT01822925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-9801 900mg
Description: 900 mg of DA-9801 in tablet form, to be taken 300 mg to be taken 3 times daily for 12 weeks.
Study NCT01822925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, in tablet form, to be taken 3 times daily for 12 weeks. The placebo is the same formulation as DA-9801 except that it does not contain the active pharmaceutical ingredient.
Study NCT01161771 — intervention group
Intervention type: PROCEDURE
Intervention: Cataract Surgery and Limbal relaxing incision
Description: Cataract extraction and limbal-relaxing incisions
Study NCT02540746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Skills Training
Description: 12-week group-based family skills training using Family Connections model
Study NCT00625898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: 6 mg/ml/min IV on day 1 every 3 weeks for cycles 1-6
Study NCT00625898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 6 mg/ml/min IV on day 1 every 3 weeks for cycles 1-6
Study NCT00625898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg IV on day 1 every 3 weeks for cycles 1-6. Following completion of chemotherapy cycles: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 1B~15 mg/kg IV on day 1 every 3 weeks for cycles 1-3. 21 days after the last dose of FEC: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 2B
Study NCT00625898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: 600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
Study NCT00625898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
Study NCT00625898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 90 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
Study NCT00625898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 90 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
Study NCT00625898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
Study NCT00625898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
Study NCT04534036 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PDS-08
Description: PDS-08 is a novel synbiotic comprised of nine probiotic bacterial strains and FOS-inulin as a prebiotic.
Study NCT01385891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine VP 16 ciclophospahamide
Description: Clofarabine intravenously 2-hour infusion,dose 40 mg/m2, followed by Etoposide (VP 16)100 mg/m2 i.v. over 2 hours and Cyclophosphamide 440 mg/m2 i.v. over 1 hour
Study NCT03707691 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listening tests. Pitch training protocol
Description: The two training protocols consists of perceptual tasks (auditory or visual exercises) performed repetitively using a tablet. Each protocol consists in 30 sessions of \~20 minutes performed at home over a period of 15 weeks.
Study NCT03707691 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: visuo-spatial training protocol
Description: The two training protocols consists of perceptual tasks (auditory or visual exercises) performed repetitively using a tablet. Each protocol consists in 30 sessions of \~20 minutes performed at home over a period of 15 weeks.
Study NCT03707691 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EEG/MEG/MRI recordings.
Description: Listening tests. EEG/MEG/MRI recordings
Study NCT03234088 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Daily weight measured by digital scale and symptom reporting
Description: All subjects will be provided the intervention.
Study NCT01591304 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin.
Study NCT01185782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonalef® (Follitropin alfa)
Description: Subcutaneous administration of follitropin alfa at a dose of 75 IU/day was started on dosing Day 1 and the same daily dose was maintained for the first 7 days of the treatment period. Dose increment by 37.5 IU was permitted on dosing Day 8, Day 15 and Day 22 if the dosage increase criterion was met.
Study NCT01185782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Purified pituitary gonadotropin (Fertinorm-P®)
Description: Subcutaneous administration of purified pituitary gonadotropin at a dose of 75 IU/day was started on dosing Day 1 and the same daily dose was maintained for the first 7 days of the treatment period. Dose increment by 37.5 IU was permitted on dosing Day 8, Day 15 and Day 22 if the dosage increase criterion was met.
Study NCT01998711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory group
Description: Five 1-1.5 hour weekly session of memory training
Study NCT03133039 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery, bioabsorbable screw
Description: In this study we compare bioabsorbable and titanium screw in the hallux valgus and hallux rigidus surgery
Study NCT02154776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: 3 weeks on and 1 week off
Study NCT02154776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib
Description: daily
Study NCT02154776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg daily;
Study NCT05108662 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery method
Description: Patients were subdivided into two groups according to their prostate volume
Study NCT03240965 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FEES (flexible endoscopic evaluation of swallowing)
Description: Endoscopical swallowing study in stroke patients only
Study NCT03240965 — intervention group
Intervention type: OTHER
Intervention: Sensitivity threshold
Description: Determining sensitivity threshold using a pudendal electrode
Study NCT03240965 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Taste-/smell-test
Description: Taste-/smell-test
Study NCT00444600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide + laser
Description: 4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
Study NCT00444600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab + laser
Description: 0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
Study NCT00444600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham injection + laser
Description: Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
Study NCT00444600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab + deferred laser
Description: 0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
Study NCT01674647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K antagonist (VKA)
Description: VKA orally once daily titrated to a target international normalized ratio (INR) of 2.5 (range 2.0-3.0, inclusive); the VKA type (eg, warfarin, acenocoumarol, phenprocoumon, fluindione, etc) will be assigned by the investigator according to local treatment standards
Study NCT00117403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E, Vitamin C, and Alpha-lipoic Acid
Description: vitamin E 800 IU, vitamin C 200 mg, and alpha-lipoic acid 600 mg formulated into three capsules, one capsule given three times per day with meals
Study NCT00117403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q
Description: 400 mg, compounded as a wafer, two wafers three times per day with meals
Study NCT00117403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsules
Description: one placebo capsule three times per day with meals
Study NCT03996278 — intervention group
Intervention type: OTHER
Intervention: Grafalon
Description: None interventional study but there are two groups
Study NCT03740009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bazedoxifene/Conjugated Estrogen
Description: 20 mg bazedoxifene/0.45mg conjugated estrogens tablets
Study NCT01394510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 600 mg N-acetylcysteine (NAC) twice daily by mouth for 2 weeks followed by 1200 mg NAC twice daily by mouth for 2 additional weeks.
Study NCT00819325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: pioglitazone 30mg p.o. once a day for 6 months
Study NCT00819325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral hypoglycemic agents
Description: sulfonylurea or metformin
Study NCT00819325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral hypoglycemic agents
Description: sulfonylurea or metformin
Study NCT03474822 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood-stage infection of P.vivax
Description: The P. vivax infected blood will be confirmed to follow the national standard of blood donation to ensure that only P. vivax is included, excluding the presence of P. falciparum. Exclude other infectious diseases according to the test of national standard of blood donation.
Study NCT02539108 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® Quadrivalent Influenza Vaccine, No Preservative
Description: 0.25 mL, Intramuscular (Pediatric Dose, 2015 2016 formulation)
Study NCT02539108 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® Quadrivalent Influenza Vaccine, No Preservative
Description: 0.5 mL, Intramuscular (2015 2016 formulation)
Study NCT01981837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-TTRSC (revusiran) for subcutaneous administration
Study NCT02976116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib will be administered orally once daily from Day 1 to Day 21 per 28-day cycle until disease progression or unacceptable toxicity
Study NCT02976116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib will be administered orally once daily per 28-day cycle or unacceptable toxicity
Study NCT04534036 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sachets will contain potato or tapioca maltodextrin.
Study NCT03497429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib capsule
Study NCT03121833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: Recombinant Human Endostatin Injection
Study NCT03121833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500ml 0.9% sodium chloride
Study NCT03121833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIM regimen / GT regimen
Description: Pirarubicin (THP) + Ifosfamide (IFO) / Docetaxel (TXT) + Gemcitabine (GEM)
Study NCT03121833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AIM regimen / GT regimen
Description: Pirarubicin (THP) + Ifosfamide (IFO) / Docetaxel (TXT) + Gemcitabine (GEM)
Study NCT03799926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patiromer
Description: Patiromer starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
Study NCT03799926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patiromer
Description: Patiromer starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
Study NCT03799926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
Study NCT03799926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
Study NCT03799926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patiromer
Description: Patiromer starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 2)
Study NCT03799926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patiromer
Description: Patiromer starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 2)
Study NCT03799926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patiromer
Description: Patiromer starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 3)
Study NCT03799926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patiromer
Description: Patiromer starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 3)
Study NCT00762372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desflurane
Description: volatile liquid for inhalation
Study NCT00762372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desflurane/nitrous oxide
Description: volatile liquid for inhalation with gas for inhalation
Study NCT00762372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane/nitrous oxide
Description: volatile liquid for inhalation and gas for inhalation
Study NCT03364335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leu Sil 1.0mg
Description: Leu 1100 mg + 1mg Sil BID
Study NCT03364335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leu Sil 4.0mg
Description: Leu 1100 mg + 4mg Sil BID
Study NCT03364335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leu Met Sil 1.0mg
Description: Leu 1100 mg + Met 500mg + 1mg Sil BID
Study NCT03364335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leu Met Sil 4.0mg
Description: Leu 1100 mg + Met 500mg + 4mg Sil BID
Study NCT03364335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04406935 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: treatment with the study device (NuEra)
Description: Multi-arm, prospective, multi-center, baseline-controlled study:~Arm 1: NuEra treatment using 475 KHz Arm 2: NuEra treatment using 1 MHz Arm 3: NuEra treatment using 2 MHz
Study NCT01431144 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue autograft
Description: A connective tissue autograft is harvested from the palate and grafted at the site of implant placement on the facial surface.
Study NCT01431144 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: connective tissue allograft
Description: An acellular dermal matrix allograft (Alloderm, BioHorizons, Inc, Birmingham, AL, USA) is grafted at the site of implant placement on the facial surface.
Study NCT03726619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-CHEC-uP
Description: One time online-based education about breast and cervical cancer screening procedures followed by phone counseling by trained community health worker over 6 months
Study NCT03726619 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CHEC-uP
Description: One time face-to-face education about breast and cervical cancer screening procedures followed by phone counseling by trained community health worker over 6 months
Study NCT01493310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone
Description: Given orally (by mouth)~Up to 4 doses of mifepristone will be studied (300 mg, 600 mg, 900 mg, 1200 mg)
Study NCT01493310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT01493310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Given by intravenous infusion (IV)~Dose of 80 mg/m2
Study NCT01493310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel
Description: Given by intravenous infusion (IV)~Dose of 80 mg/m2
Study NCT04275245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meplazumab for Injection
Description: humanized MAb against CD147
Study NCT00360698 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Insulin Glargine
Description: One daily injection at bedtime
Study NCT00360698 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Glimepiride
Description: At same dosage as during the run-in period
Study NCT01967745 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic appendectomy
Description: The laparoscopic appendectomy was performed with three trocars. Pneumoperitoneum was created using an open Hasson technique. The mesoappendix was divided using a harmonic scalpel or endoscopic tissue fusion device. The appendix was divided by placing one endoscopic loop and cut with harmonic scalpel. The specimen was removed through the umbilical port.
Study NCT01967745 — intervention group
Intervention type: PROCEDURE
Intervention: open appendectomy
Description: The open appendectomy was carried out in the standard way with McBurney muscle splitting incision (in supine position).
Study NCT00360698 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Insulin Glulisine
Description: One bolus given before the main meal
Study NCT00360698 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: At same dosage as during the run-in period
Study NCT01043458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: ABT-126 Low Dose \& ABT-126 High Dose
Study NCT00117403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: one placebo capsule three times per day with meals
Study NCT00117403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo wafers
Description: two placebo wafers three times per day with meals
Study NCT00117403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo wafers
Description: two placebo wafers three times per day with meals
Study NCT03407118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC.
Study NCT03407118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC.
Study NCT00869024 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells
Description: Ten separate injections will be delivered into the LV free wall (20 X 106 cells / 400 micro lit).
Study NCT00869024 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells
Description: Ten separate injections will be delivered into the LV free wall (20 X 106 cells / 400 micro lit).
Study NCT04072276 — intervention group
Intervention type: BIOLOGICAL
Intervention: EV71 vaccine
Description: EV71 vaccine with Adjuvant AlPO4 and the placebo (Adjuvant AlPO4 only) were randomly administrated to subject in CT-EV-21 study
Study NCT03465748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoK
Description: orthok (orthokeratology) is the science of changing the curvature or shape of the cornea to change how light is focused on the retina at the back of one's eye. Specially designed molding retainer contact lenses are placed on the eye at night and are removed upon awakening.